IMMUNOHISTOCHEMISTRY, TDT

The IHC – TdT (Terminal Deoxynucleotidyl Transferase) test is an immunohistochemistry-based diagnostic assay used to detect TdT protein expression in tissue samples. TdT is a specialized nuclear enzyme found in immature lymphoid cells, particularly early B-cell and T-cell precursors. Because of its association with immature lymphocytes, TdT is a key marker in the diagnosis of acute leukemias and lymphoblastic lymphomas.

This test is widely used in hematopathology to identify lymphoblastic neoplasms and distinguish them from mature lymphoid malignancies. Detection of TdT expression helps pathologists determine whether abnormal cells originate from immature lymphoid precursors, which is essential for accurate diagnosis and treatment planning.

The IHC TdT test plays a crucial role in evaluating bone marrow biopsies, lymph node biopsies, and tissue samples from patients with suspected hematologic cancers.

Benefits of the Test

• Helps diagnose acute lymphoblastic leukemia (ALL)
• Assists in identifying lymphoblastic lymphoma
• Supports classification of hematologic malignancies
• Distinguishes immature from mature lymphoid tumors
• Helps guide treatment planning and prognosis evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC TdT test when evaluating suspected leukemia, lymphoma, or lymphoid malignancies. It is commonly used in:

• Acute lymphoblastic leukemia (ALL) diagnosis
• Lymphoblastic lymphoma evaluation
• Bone marrow biopsy assessment
• Lymph node pathology investigations
• Hematologic malignancy classification
• Immunophenotyping studies

TdT is frequently used alongside markers such as CD3, CD20, CD34, CD79a, CD10, PAX5, and MPO to provide comprehensive leukemia and lymphoma profiling.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a bone marrow biopsy, lymph node biopsy, or tissue specimen
• No fasting is required
• No medication restrictions are generally necessary
• Clinical findings and laboratory results may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected acute leukemia
• Individuals with suspected lymphoblastic lymphoma
• Patients undergoing bone marrow evaluation
• Cases requiring hematologic cancer classification
• Oncology and hematology patients requiring immunohistochemistry profiling

The IHC TdT test is an essential diagnostic tool in hematopathology. By identifying immature lymphoid cells, it helps clinicians accurately diagnose leukemia and lymphoma, enabling timely treatment and improved patient management.

Clinical Significance

TdT immunostaining is commonly used in the evaluation of:

• Acute lymphoblastic leukemia (ALL)
• B-lymphoblastic leukemia/lymphoma
• T-lymphoblastic leukemia/lymphoma
• Precursor lymphoid neoplasms
• Bone marrow malignancies
• Lymphoid tumors with immature cell populations

Strong nuclear TdT positivity is considered a hallmark of immature lymphoid precursor cells and is highly valuable in leukemia diagnosis.